SCI时时刷

search
The expanding CML treatment landscape: an introspective commentary
The article by Abdelmagid and co-authors on real-world experience with ponatinib that accompanies this ed...
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3 internal tandem duplication (ITD) muta...
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
Biallelic TP53 inactivation is the most important high-risk factor associated with poor survival in multiple myeloma. Clas...
Zanubrutinib: past, present, and future
Zanubrutinib: past, present, and future
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients w...
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Variability in the molecular response to frontline tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia may...
Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia
Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia
Acute myeloid leukemia (AML) can be classified into multiple genetic subtypes based on recurrent pathogen...
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis
Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for Waldenstrom macroglobulinaemia (WM)...
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
The deregulation of BCL2 family proteins plays a crucial role in leukemia development. Therefore, pharmacological inhibiti...
Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease
Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease
Prolonged viral shedding (PVS) results from a failure of viral eradication. Before the emergence of SARS-...
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
Testing for measurable residual disease (MRD) in persons with plasma cell myeloma (PCM) after therapy cor...
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor ou...
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, CanadaArleigh McCurdy & Alissa VisramJuravinski C...
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative in some, while toxic in many ...
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted t...